| Role of antioxidants in prophylaxis and therapy: A pharmaceutical perspective DV Ratnam, DD Ankola, V Bhardwaj, DK Sahana, MNV Kumar Journal of Controlled Release 113 (3), 189-207, 2006 | 1385 | 2006 |
| Estradiol loaded PLGA nanoparticles for oral administration: effect of polymer molecular weight and copolymer composition on release behavior in vitro and in vivo G Mittal, DK Sahana, V Bhardwaj, MNVR Kumar Journal of Controlled Release 119 (1), 77-85, 2007 | 657 | 2007 |
| Fundamentals and applications of controlled release drug delivery J Siepmann, RA Siegel, MJ Rathbone Springer 3, 33-34, 2012 | 591* | 2012 |
| PLGA nanoparticles for oral delivery of hydrophobic drugs: influence of organic solvent on nanoparticle formation and release behavior in vitro and in vivo using estradiol as a … DK Sahana, G Mittal, V Bhardwaj, MNV Kumar Journal of pharmaceutical sciences 97 (4), 1530-1542, 2008 | 329 | 2008 |
| Nanoparticle technology for drug delivery RB Gupta, UB Kompella Taylor & Francis Group, LLc, 2006 | 326 | 2006 |
| Analytical methods for assay of ellagic acid and its solubility studies I Bala, V Bhardwaj, S Hariharan, MNV Kumar Journal of pharmaceutical and biomedical analysis 40 (1), 206-210, 2006 | 325 | 2006 |
| Design of estradiol loaded PLGA nanoparticulate formulations: a potential oral delivery system for hormone therapy S Hariharan, V Bhardwaj, I Bala, J Sitterberg, U Bakowsky, MNVR Kumar Pharmaceutical research 23 (1), 184-195, 2006 | 324 | 2006 |
| PLGA nanoparticles for oral delivery of cyclosporine: Nephrotoxicity and pharmacokinetic studies in comparison to Sandimmune Neoral® JL Italia, DK Bhatt, V Bhardwaj, K Tikoo, MNV Kumar Journal of controlled release 119 (2), 197-206, 2007 | 268 | 2007 |
| Can controversial nanotechnology promise drug delivery? VR Devadasu, V Bhardwaj, MNVR Kumar Chemical reviews 113 (3), 1686-1735, 2013 | 248 | 2013 |
| PLGA nanoparticles stabilized with cationic surfactant: safety studies and application in oral delivery of paclitaxel to treat chemical-induced breast cancer in rat V Bhardwaj, DD Ankola, SC Gupta, M Schneider, CM Lehr, MNVR Kumar Pharmaceutical research 26 (11), 2495-2503, 2009 | 184 | 2009 |
| Design and evaluation of biodegradable, biosensitive in situ gelling system for pulsatile delivery of insulin N Kashyap, B Viswanad, G Sharma, V Bhardwaj, P Ramarao, ... Biomaterials 28 (11), 2051-2060, 2007 | 168 | 2007 |
| Development of biodegradable nanoparticles for oral delivery of ellagic acid and evaluation of their antioxidant efficacy against cyclosporine A-induced nephrotoxicity in rats K Sonaje, JL Italia, G Sharma, V Bhardwaj, K Tikoo, MNVR Kumar Pharmaceutical research 24 (5), 899-908, 2007 | 166 | 2007 |
| Development of potent oral nanoparticulate formulation of coenzyme Q10 for treatment of hypertension: Can the simple nutritional supplements be used as first line therapeutic … DD Ankola, B Viswanad, V Bhardwaj, P Ramarao, MNV Kumar European Journal of Pharmaceutics and Biopharmaceutics 67 (2), 361-369, 2007 | 163 | 2007 |
| Sustained release nanoparticulate formulation containing antioxidant-ellagic acid as potential prophylaxis system for oral administration I Bala, V Bhardwaj, S Hariharan, SV Kharade, N Roy, MNV Ravi Kumar Journal of drug targeting 14 (1), 27-34, 2006 | 138 | 2006 |
| Pharmaceutical aspects of polymeric nanoparticles for oral drug delivery V Bhardwaj, S Hariharan, I Bala, A Lamprecht, N Kumar, R Panchagnula, ... Journal of Biomedical Nanotechnology 1 (3), 235-258, 2005 | 98 | 2005 |
| Disease, destination, dose and delivery aspects of ciclosporin: the state of the art JL Italia, V Bhardwaj, MNVR Kumar Drug discovery today 11 (17-18), 846-854, 2006 | 96 | 2006 |
| Design of biodegradable nanoparticles: a novel approach to encapsulating poorly soluble phytochemical ellagic acid I Bala, V Bhardwaj, S Hariharan, J Sitterberg, U Bakowsky, MNVR Kumar Nanotechnology 16 (12), 2819, 2005 | 88 | 2005 |
| Nanotherapeutics: drug delivery concepts in nanoscience A Lamprecht CRC Press, 2016 | 63 | 2016 |
| Surface area normalized dissolution to study differences in itraconazole-copovidone solid dispersions prepared by spray-drying and hot melt extrusion V Bhardwaj, NS Trasi, DY Zemlyanov, LS Taylor International journal of pharmaceutics 540 (1-2), 106-119, 2018 | 57 | 2018 |
| Fixed dose combinations for tuberculosis: lessons learned from clinical, formulation and regulatory perspective R Panchagnula, S Agrawal, Y Ashokraj, M Varma, K Sateesh, V Bhardwaj, ... Methods Find Exp Clin Pharmacol 26 (9), 703-721, 2004 | 57 | 2004 |
Kiran SonajeHead R&D, Axio Biosolutions Pvt. Ltd.כתובת אימייל מאומתת בדומיין axiobio.com